CLARITIN HIVES RELIEF Drug Patent Profile

When do Claritin Hives Relief patents expire, and what generic alternatives are available?

Claritin Hives Relief is a drug marketed by Bayer Healthcare Llc and is included in three NDAs.

The generic ingredient in CLARITIN HIVES RELIEF is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin Hives Relief

A generic version of CLARITIN HIVES RELIEF was approved as loratadine by PLD ACQUISITIONS LLC on January 21^st, 2003.

Summary for CLARITIN HIVES RELIEF

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	148
Clinical Trials:	27
Patent Applications:	3,937
DailyMed Link:	CLARITIN HIVES RELIEF at DailyMed

Recent Clinical Trials for CLARITIN HIVES RELIEF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andover Research Eye Institute	Phase 4
Rutgers, The State University of New Jersey	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all CLARITIN HIVES RELIEF clinical trials

US Patents and Regulatory Information for CLARITIN HIVES RELIEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN HIVES RELIEF	loratadine	SYRUP;ORAL	020641-003	Nov 19, 2003		DISCN	Yes	No
Bayer Healthcare Llc	CLARITIN HIVES RELIEF	loratadine	TABLET;ORAL	019658-003	Nov 19, 2003		OTC	Yes	Yes
Bayer Healthcare Llc	CLARITIN HIVES RELIEF REDITAB	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-003	Nov 19, 2003		OTC	Yes	Yes

International Patents for CLARITIN HIVES RELIEF

See the table below for patents covering CLARITIN HIVES RELIEF around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	123325	STABILIZED ANTIHISTAMINE SYRUP
Australia	4337289
Luxembourg	90738
Finland	90977
Finland	82934

Supplementary Protection Certificates for CLARITIN HIVES RELIEF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

CLARITIN HIVES RELIEF Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Claritin: A Comprehensive Analysis

Introduction to Claritin

Claritin, a well-known brand of the antihistamine loratadine, is a staple in the treatment of allergic conditions such as hay fever, hives, and other allergies. Here, we delve into the market dynamics and financial trajectory of Claritin, highlighting key drivers, challenges, and future projections.

Market Size and Forecast

The Claritin market was valued at USD 0.16 billion in 2023 and is projected to reach USD 0.26 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.67% during the forecast period of 2024-2031[1].

Global Market Drivers

Several factors drive the growth of the Claritin market:

Product Innovation

Continuous research and development have led to novel formulations, including extended-release variants and combination medicines. These innovations enhance convenience and efficacy, appealing to consumers seeking better allergy relief[1].

Alterations in Lifestyle Factors

Urbanization and increased exposure to allergens such as pollen, dust mites, and pet dander have resulted in higher demand for allergy treatments. This shift in lifestyle factors contributes significantly to the market growth[1].

Seasonal Demand

Seasonal allergies, particularly during spring and autumn, drive up the demand for allergy relief medicines like Claritin. This periodic increase in demand is a key market driver[1].

Promotions and Marketing

Effective marketing strategies, including commercials and promotions, enhance brand awareness and stimulate sales. Strong marketing efforts are crucial for maintaining and expanding the consumer base[1].

Global Expansion

The expansion of Claritin into new markets and regions increases its consumer base and potential revenue. This geographical diversification is vital for sustained growth[1].

Challenges and Constraints

Despite the growth drivers, the Claritin market faces several challenges:

Competition from Generic Brands

Generic loratadine products, available at lower prices, can erode the market share of branded Claritin, impacting profitability. The presence of generic alternatives is a significant competitive threat[1].

Market Saturation

The antihistamine market is saturated with numerous established brands, making it challenging for Claritin to sustain growth. This saturation complicates marketing and distribution efforts[1].

Adverse Effects and Consumer Reservations

Some consumers may be hesitant to use antihistamines due to potential side effects, such as drowsiness, although Claritin is non-drowsy. This consumer skepticism can hinder widespread acceptance[1].

Regulatory Challenges

Changes in legislation or constraints on advertising and marketing can influence the promotion and sale of Claritin. Regulatory hurdles are a constant concern for pharmaceutical companies[1].

Economic Factors

Economic recessions or fluctuations can impact consumer spending on healthcare products, including allergy medications. Economic instability can affect market performance[1].

Changes in Consumer Preferences

Increasing trends towards natural and holistic health treatments may lead consumers to seek alternatives to traditional drugs like Claritin. This shift in consumer preferences is a potential threat[1].

Geographical Segmentation

The Claritin market is segmented geographically into several key regions:

North America

North America, particularly the United States and Canada, has significant market penetration due to strong brand recognition and high prevalence of allergic conditions. Effective marketing strategies and consumer trust drive this market[1].

Europe

Europe, with countries like Germany and the UK, shows substantial demand driven by rising pollen levels and increased awareness about allergic rhinitis[1].

Asia-Pacific

The Asia-Pacific region is emerging as a significant market due to a growing population, urbanization, and higher disposable income, leading to increased healthcare spending and awareness of allergy-related products[1].

Latin America, Middle East, and Africa

These regions present unique challenges and opportunities. Latin America is witnessing a gradual rise in acceptance and demand for allergy medications, while the Middle East and Africa face varying healthcare infrastructure challenges but also growing demand[1].

Distribution Channels

The distribution of Claritin is facilitated through various channels:

Online Retail

Online retail has emerged as a dynamic sub-segment, experiencing significant growth due to increasing digital penetration and the convenience of home delivery. This channel appeals to tech-savvy consumers and those who prefer privacy in their purchasing[1].

Health Stores

Health stores, focusing on natural and over-the-counter remedies, cater to health-conscious consumers seeking specialized products and personalized service. These stores enrich the overall market landscape by providing diverse accessibility[1].

Human Antihistamine Drug Market Context

The broader human antihistamine drug market provides context for Claritin's performance. This market is expected to grow from USD 274.8 million in 2023 to USD 706.2 million by 2033, at a CAGR of 9.9%[3].

Dominant Drug Type

Second-generation antihistamines, like Claritin, hold over 62.7% of the market share in 2023, emphasizing their improved safety profiles and reduced sedative effects[3].

Preferred Medication Type

Over-the-counter (OTC) drugs, which include Claritin, lead with a 60.7% market share in 2023, reflecting consumer preference for accessible, non-prescription solutions[3].

Key Players

The Claritin market involves several major players:

Bayer AG, Sanofi, Pfizer, Johnson & Johnson, and Merck

These companies are significant in the antihistamine market and influence the competitive landscape through their marketing strategies, product innovations, and global reach[1].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on the healthcare sector, including the antihistamine market. Studies have explored the use of antihistamines like loratadine in treating COVID-19-related symptoms, which has influenced market dynamics[4].

Financial Trajectory

The financial trajectory of Claritin is marked by steady growth, driven by the factors mentioned above. Here are some key financial highlights:

• Market Size: Projected to reach USD 0.26 billion by 2031 from USD 0.16 billion in 2023[1].
• CAGR: Expected to grow at a CAGR of 5.67% during the forecast period 2024-2031[1].
• Revenue Growth: The broader human antihistamine drug market is expected to grow significantly, providing a favorable context for Claritin’s financial performance[3].

Key Takeaways

• Claritin’s market is driven by product innovation, lifestyle changes, seasonal demand, and effective marketing.
• The market faces challenges from generic brands, market saturation, and changes in consumer preferences.
• Geographical segmentation highlights North America, Europe, and the Asia-Pacific region as key markets.
• Distribution channels, including online retail and health stores, are crucial for market penetration.
• The broader human antihistamine drug market is growing at a CAGR of 9.9%, supporting Claritin’s financial trajectory.

Frequently Asked Questions (FAQs)

1. What is the projected market size of Claritin by 2031?

The Claritin market is projected to reach USD 0.26 billion by 2031[1].

2. What is the CAGR of the Claritin market during the forecast period?

The Claritin market is expected to grow at a CAGR of 5.67% during the forecast period 2024-2031[1].

3. What are the main drivers of the Claritin market?

The main drivers include product innovation, alterations in lifestyle factors, seasonal demand, and effective marketing strategies[1].

4. How does the presence of generic brands affect the Claritin market?

The presence of generic loratadine products at reduced prices can erode the market share of branded Claritin, impacting profitability[1].

5. What is the significance of online retail in the distribution of Claritin?

Online retail has emerged as a dynamic sub-segment, experiencing significant growth due to increasing digital penetration and the convenience of home delivery, which appeals to tech-savvy consumers and those who prefer privacy in their purchasing[1].

Sources:

1. Verified Market Research. Claritin Market Size, Share, Growth, Trends & Forecast.
2. Sanofi. Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria.
3. Market.US. Human Antihistamine Drug Market Size | CAGR OF 9.9%.
4. Mordor Intelligence. Loratadine Market - Size, Analysis, Industry Share & Growth.